AstraZeneca’s Lokelma Receives Fast Track Designation for the Treatment of Chronic Haemodialysis with Hyperkalaemia
Shots: The designation is based on the ongoing P-III DIALIZE-Outcomes trial to evaluate the effect of Lokelma on arrhythmia-related CV outcomes in patients with chronic hemodialysis with recurrent HK at 300 sites across the US, Canada, Russia, EU, Asia & South America The therapy is designed to reduce serious adverse CV outcomes. The results are […]